This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Eriksson, M. Articles by Runmarker, B. Search for Related Content PubMed PubMed Citation Articles by Eriksson, M. Articles by Runmarker, B. Pubmed/NCBI databases Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis

Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden

Oluf Andersen

Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden, oluf.andersen{at}neuro.gu.se

Björn Runmarker

Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden

This paper extends on previous data on prognosis in multiple sclerosis (MS), to encompass the entire course of the disease. The first episode suggestive of MS [the clinically isolated syndrome (CIS)] was included as a starting point, and the speed of secondary progression as an end point. Primary progressive MS was not included. Unique preconditions, with one neurological service covering the G öteborg district, allowed for establishing a strictly population-based, essentially untreated 15-year incidence cohort of 308 MS patients who were followed for 25 years. Survival analysis was performed as Kaplan -Meyer graphs, and independent predictors were ascertained by C ox regression analysis. A matrix of several predictors and end points was created. From C IS, a higher risk of developing clinically definite MS (C DMS), secondary progressive course and Disability Status Scale 7 (DSS7) was predicted by efferent tract lesions. However, less than 25% had reached DSS7 25 years after C IS with pure afferent lesions or other favorable predicto rs. During the first five years, higher relapse frequency, as well as incomplete remission of early bouts, predicted higher risks of secondary progressive course and DSS7 during follow-up to 25 years. However, these early predictors were unable to predict the rate of progression, which seems to contain an element of the disease process unassociated with its early events. O nly late predictors, such as a shorter time from onset to secondary progression (1-10 years) and a higher number of functional systems involved at onset of progression predicted a faster progression rate. Predictors from this study could be used to refine historically controlled trials.

Key Words: epidemiology • multiple sclerosis • prognosis • survival analysis

Multiple Sclerosis, Vol. 9, No. 3, 260-274 (2003)
DOI: 10.1191/1352458503ms914oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Tremlett, M. Yousefi, V. Devonshire, P. Rieckmann, Y. Zhao, and On behalf of the UBC Neurologists Impact of multiple sclerosis relapses on progression diminishes with time Neurology, November 17, 2009; 73(20): 1616 - 1623. [Abstract] [Full Text] [PDF]

				J. K. Swanton, K. T. Fernando, C. M. Dalton, K. A. Miszkiel, D. R. Altmann, G. T. Plant, A. J. Thompson, and D. H. Miller Early MRI in optic neuritis: The risk for disability Neurology, February 10, 2009; 72(6): 542 - 550. [Abstract] [Full Text] [PDF]

				M. Leone, S. Bonissoni, L. Collimedaglia, F. Tesser, S. Calzoni, A. Stecco, P. Naldi, and F. Monaco Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study Multiple Sclerosis, May 1, 2008; 14(4): 485 - 493. [Abstract] [PDF]

				H. Tremlett, Yinshan Zhao, and V. Devonshire Natural history of secondary-progressive multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 314 - 324. [Abstract] [PDF]

				L. K. Fisniku, P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton, R. Lanyon, A. J. Thompson, and D. H. Miller Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis Brain, March 1, 2008; 131(3): 808 - 817. [Abstract] [Full Text] [PDF]

				A. Langer-Gould, R. A. Popat, S. M. Huang, K. Cobb, P. Fontoura, M. K. Gould, and L. M. Nelson Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis: A Systematic Review Arch Neurol, December 1, 2006; 63(12): 1686 - 1691. [Abstract] [Full Text] [PDF]

				C. Confavreux and S. Vukusic Age at disability milestones in multiple sclerosis Brain, March 1, 2006; 129(3): 595 - 605. [Abstract] [Full Text] [PDF]

				C. Confavreux and S. Vukusic Natural history of multiple sclerosis: a unifying concept Brain, March 1, 2006; 129(3): 606 - 616. [Abstract] [Full Text] [PDF]

				A. Chaudhuri Lessons for clinical trials from natalizumab in multiple sclerosis. BMJ, February 18, 2006; 332(7538): 416 - 419. [Full Text] [PDF]

				K. T. M. Fernando, D. J. Tozer, K. A. Miszkiel, R. M. Gordon, J. K. Swanton, C. M. Dalton, G. J. Barker, G. T. Plant, A. J. Thompson, and D. H. Miller Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis Brain, December 1, 2005; 128(12): 2911 - 2925. [Abstract] [Full Text] [PDF]